Abstract
Urinary tract infections are one of the most common bacterial infections worldwide; however, increasing antimicrobial resistance in bacterial pathogens is making it challenging for clinicians to correctly prescribe patients appropriate antibiotics. In this study, we present four interpretable machine learning-based decision support systems for predicting antimicrobial resistance. Using electronic health record data from a large cohort of patients diagnosed with complicated UTIs, we demonstrate high predictability of antibiotic resistance across four antibiotics – nitrofurantoin, co-trimoxazole, ciprofloxacin, and levofloxacin. We additionally demonstrate the generalizability of our methods on a separate cohort of patients with uncomplicated UTIs. Through our study, we demonstrate that machine learning-based methods can help reduce the risk of non-susceptible treatment, facilitate rapid clinical intervention, enable more personalized approaches for treatment recommendation, while additionally allowing model interpretability that explains the basis for predictions.
Competing Interest Statement
DAC reports personal fees from Oxford University Innovation, personal fees from BioBeats, personal fees from Sensyne Health, outside the submitted work. DWE declares lecture fees from Gilead outside of the submitted work. No other authors report any conflicts of interest.
Funding Statement
This work was supported by the Oxford National Institute of Research (NIHR) Biomedical Research Campus (BRC). JY is a Marie Sklodowska-Curie Fellow, under the European Union Horizon 2020 research and innovation programme (Grant agreement: 955681, MOIRA). DWE is funded by a Robertson Foundation Fellowship. The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the manuscript. The views expressed are those of the authors and not necessarily those of the NIHR or the EU Commission.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The AMR-UTI dataset is a publicly-available, anonymized dataset, approved by the Institutional Review Board (IRB) of Massachusetts General Hospital with a waived requirement for informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The AMR-UTI data can be downloaded from: https://physionet.org/content/antimicrobial-resistance-uti/1.0.0/.
https://physionet.org/content/antimicrobial-resistance-uti/1.0.0/